Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)

Chronic Idiopathic Constipation Clinical Trial

— CIC  

Official title:

A Prospective, Multicenter, Randomized, Single Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04458675
• Other study ID #: 250CLD
• Status: Completed
• Phase: Phase 4
• Start date: July 26, 2018
• Est. completion date: March 30, 2019

Study information

• Verified date: July 2023
• Source: Vibrant Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The was performed to assess the safety and efficacy of the vibrant capsule vs. placebo for the treatment of subjects with functional Constipation.

Description:

Visit 1 -Screening: Subjects will be screened to the study at the screening visit, PAC-QOL questionnaire will be completed and subject will have a run-in time for a period of 2-3 weeks, assuring 14 consecutive days of eDiary with an average of < 3 SBM per week. Visit 2 - Baseline: After the run-in period, the subjects will return and eligibility will be re-assessed. Subjects will be randomized to either Vibrant or Vibrant placebo for a treatment period of 8 weeks. Subjects, in both arms, will have their first administration of Vibrant capsule / Vibrant placebo on site at the day of baseline visit and will be instructed on their treatment administration at home and will be requested to ingest the capsules at a specific time of the day. At baseline, subjects will also be trained on how to use the base unit at home. Subjects will be instructed to complete a simple subject eDiary each day throughout the duration of the study (including the run-in period). The eDiary will include questions on: - Daily BM, SBM, CSBM - Change of their diet, if applicable (NOTE: the protocol will not ask/require the subjects to change anything in his/her diet) - Change in sympotms as: brisol stool consistancy, straining, bloating, and the other questions in the eDiary - Medication - AE (including diarhrea) The first 2 weeks of treatment will be considered as a subjects' training period. Visit 3 -after 4 weeks of treatment - an on site visit will take place to evaluate subject's safety and treatment efficacy and additional capsule dispencing. Visit 4 Final visit -after another 4 weeks of treatment - an on site visit will take place to evaluate subject's safety and treatment efficacy and collect the base unites and remaning capsules. PAC-QOL, Ease of use and TSQM questionnaires will be completed. During the entire study period, data reporting will be done on an electronic Case Report Form (eCRF) and an eDiary. Subjects will be asked to refrain from taking any medication or supplement to relieve their constipation, during the entire study period. Subjects will receive phone calls at least once a week and subject compliance will be monitored throughout the 8 weeks of the study. Subjects will be authorized to use rescue medication after 3 consecutive days without a bowel movement. Data about time of activation of the capsules will be automatically registered and transmitted by the base unit for Vibrant capsules

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: March 30, 2019
• Est. primary completion date: January 7, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

1. Subjects aged 22 years and older

2. Subjects with Chronic Idiopathic Constipation (CIC) according to Rome III criteria and who have not experienced relief of their symptoms from available therapies (osmotic and stimulant laxatives used for at least one month at recommended dose)

3. Subjects with an average of <3 Spontaneous Bowel Movements (SBM) per week

4. Normal colonoscopy performed within 5 years prior to study participation, unless the subjects are <50 years old and without alarm signs and/or symptoms

5. Subject signed the Informed Consent Form (ICF)

6. Female subjects must have a negative blood pregnancy test during screening, confirmed by a negative urine pregnancy test during baseline and must not be lactating prior to receiving study medication. For females of child-bearing potential, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. All other female subjects must have the reason for their inability to bear children documented in the medical record [i.e., tubal ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period)]; in these circumstances, a pregnancy test will not be necessary

Exclusion Criteria:

1. History of complicated/obstructive diverticular disease

2. History of intestinal or colonic obstruction, or suspected intestinal obstruction.

3. History of significant gastrointestinal disorder, including any form of inflammatory bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has been treated and is in remission)

4. History of gastroparesis

5. Use of any of the following medications:

• Medications that may affect intestinal motility, prokinetics, anti-Parkinsonian medications, opiates, opioids, calcium-channel blockers, aluminum/magnesium hydroxide
• With the exception of antidepressants, thyroid or hormonal replacement therapy, when the subject has been on a stable dose for at least 3 months prior to enrollment.

6. Clinical evidence of significant respiratory, cardiovascular, renal, hepatic, biliary, endocrine, psychiatric or neurologic disease.

7. Presence of cardiac pacemaker or gastric electrical stimulator.

8. History of, or current eating disorders, such as anorexia, bulimia, or compulsory overeating.

9. Diagnosis of mega-rectum or colon, congenital anorectal malformation, clinically significant rectocele, history of intestinal resection (with an exception for appendectomy, cholecystectomy and inguinal hernia repair), history of bariatric surgery or evidence of any structural abnormality of the gastrointestinal tract that might affect transit

10. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal stricture or achalasia

11. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs): chronic use is defined as taking full dose NSAIDs more than three times a week for at least six months. Subjects on cardiac doses of aspirin may be enrolled in the study

12. Subjects with pelvic floor dysfunction/defecatory disorder, based on subject history

13. Participation in another clinical study within one month prior to screening.

14. Women who are pregnant or lactating

15. Use of any medication for constipation relief during the study, except as rescue medication, as indicated by study rules

16. Inability to use an electronic daily Diary (on a computer, phone application, tablet or other electronic device) to report bowel movements, symptoms and medication usage

17. Subject participated in a previous Vibrant study

18. Any other condition which in the opinion of the investigator may adversely affect the safety of the subject or would limit the subject's ability to complete the study

Related Conditions & MeSH terms

• Chronic Idiopathic Constipation
• Constipation

Intervention

Device:
• Vibrant capsule
The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility

Drug:
• Placebo
A biodegradable capsule, which visually similar to the Vibrant active capsule

Locations

Country	Name	City	State
United States	Health Research of Hampton Roads	Newport News	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Vibrant Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CSBM success rate: An increase from the run-in period of at least one weekly Complete Spontaneous Bowel Movement (CSBM)	The primary efficacy endpoint is CSBM success rate, defined as an increase from the run-in period of at least one weekly Complete Spontaneous Bowel Movement (CSBM) during at least 6 of the 8 weeks of treatment	change from baseline to 8 weeks
Primary	all adverse events related and unrelated to the study treatment	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	through study completion, an average of 1 year
Secondary	SBM success rate	an increase from the run-in period of at least one weekly Spontaneous Bowel Movement (SBM) during at least 6 of the 8 weeks of treatment	change from baseline to 8 weeks
Secondary	average stool consistency	the stool consistency is evaluated using the Bristol scale	change from baseline to 8 weeks
Secondary	average straining	A sacle of 0-10	change from baseline to 8 weeks
Secondary	PAC-QoL	patient's questionnaire to evaluate quality of life	change from baseline to 8 weeks